391 related articles for article (PubMed ID: 19769866)
1. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study].
Baeteman C; Hoffart L; Galland F; Ridings B; Conrath J
J Fr Ophtalmol; 2009 May; 32(5):309-13. PubMed ID: 19769866
[TBL] [Abstract][Full Text] [Related]
2. A new grading system for retinal pigment epithelial tears.
Sarraf D; Reddy S; Chiang A; Yu F; Jain A
Retina; 2010; 30(7):1039-45. PubMed ID: 20458264
[TBL] [Abstract][Full Text] [Related]
3. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
4. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
5. [Feeder vessel treatment of choroidal neovascularization in age-related macular degeneration].
Coscas F; Stanescu D; Coscas G; Soubrane G
J Fr Ophtalmol; 2003 Jun; 26(6):602-8. PubMed ID: 12910200
[TBL] [Abstract][Full Text] [Related]
6. Retinal pigment epithelial tear after intravitreal ranibizumab.
Bakri SJ; Kitzmann AS
Am J Ophthalmol; 2007 Mar; 143(3):505-7. PubMed ID: 17317396
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
8. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
9. Tears of the retinal pigment epithelium: an old problem in a new era.
Chang LK; Sarraf D
Retina; 2007 Jun; 27(5):523-34. PubMed ID: 17558312
[TBL] [Abstract][Full Text] [Related]
10. Retinal pigment epithelial tears in ranibizumab-treated eyes.
Smith BT; Kraus CL; Apte RS
Retina; 2009 Mar; 29(3):335-9. PubMed ID: 19174716
[TBL] [Abstract][Full Text] [Related]
11. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Garg S; Brod R; Kim D; Lane RG; Maguire J; Fischer D
Clin Exp Ophthalmol; 2008 Apr; 36(3):252-6. PubMed ID: 18412594
[TBL] [Abstract][Full Text] [Related]
12. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
14. [Pars plana vitrectomy, subretinal injection of recombinant tissue plasminogen activator and fluid-gas exchange in the management of massive submacular hemorrhages secondary to age-related macular degeneration].
Auriol S; Mahieu L; Lequeux L; Quintyn JC; Pagot-Mathis V
J Fr Ophtalmol; 2010 Feb; 33(2):84-91. PubMed ID: 20092910
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic approaches to age-related macular degeneration today.
Bressler NM
Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
[TBL] [Abstract][Full Text] [Related]
16. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
17. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
Rosenfeld PJ; Schwartz SD; Blumenkranz MS; Miller JW; Haller JA; Reimann JD; Greene WL; Shams N
Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
[TBL] [Abstract][Full Text] [Related]
18. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration.
Hwang JC; Del Priore LV; Freund KB; Chang S; Iranmanesh R
Ophthalmic Surg Lasers Imaging; 2011; 42(1):6-11. PubMed ID: 20954648
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of macular hematoma after ranibizumab treatment for age-related macular degeneration.
Azar G; Mauget-Faÿsse M; Nyouma J; Cohen SY; Coscas F; Français-Maury C; Souied E; Soubrane G
Eur J Ophthalmol; 2015; 25(2):163-7. PubMed ID: 25684081
[TBL] [Abstract][Full Text] [Related]
20. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration.
Sacu S; Stifter E; Vécsei-Marlovits PV; Michels S; Schütze C; Prünte C; Schmidt-Erfurth U
Eye (Lond); 2009 Jun; 23(6):1404-10. PubMed ID: 18756282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
